APA (7th ed.) Citation

Michaeli, D., Michaeli, J., Boch, T., & Michaeli, C. T. (2022). Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy. Clinical drug investigation, 42(8), . https://doi.org/10.1007/s40261-022-01173-3

Chicago Style (17th ed.) Citation

Michaeli, Daniel, Julia Michaeli, Tobias Boch, and Christoph T. Michaeli. "Cost-effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Dtatins Compared to Statin Monotherapy." Clinical Drug Investigation 42, no. 8 (2022). https://doi.org/10.1007/s40261-022-01173-3.

MLA (9th ed.) Citation

Michaeli, Daniel, et al. "Cost-effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Dtatins Compared to Statin Monotherapy." Clinical Drug Investigation, vol. 42, no. 8, 2022, https://doi.org/10.1007/s40261-022-01173-3.